Merck progresses toward completion of Sigma-Aldrich acquisition

Closing of transaction expected within next 2 months.

“We are diligently working on fulfilling the EU commitments,” said Bernd Reckmann, Member of the Executive Board of Merck and CEO Life Science. “However, due to the complex nature of the business, the process is taking longer than originally expected. Meanwhile we’ve been making very good progress in our integration planning and are looking forward to swiftly integrating Sigma-Aldrich, which will allow us to offer customers a broader portfolio of products, greater geographic reach and an unmatched combination of industry-leading capabilities.”

Sigma-Aldrich shareholders approved the merger with Merck in December 2014. Merck has also completed its capital markets activities to finance the transaction with the placement of a €2.1 billion bond at the end of August.

The planned acquisition of Sigma-Aldrich for approximately $17 billion (€13.1 billion), which was announced in September 2014, is a key element of Merck’s “Fit for 2018” transformation and growth program. Establishing one of the leading players in the $130 billion global life science industry, the transaction presents an opportunity for both companies and their customers. Once the transaction has been completed, Merck will be able to serve life science customers around the world with a highly attractive set of established brands and an efficient supply chain that can support the delivery of more than 300,000 products.